New hope for patients with less common breast cancer
WASHINGTON - A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported recently.
Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15-20 per cent of all breast cancer cases. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. - 123RF file photo
HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread.
Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years.
"Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP.
The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug.
'Smart bomb'
This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney.
"Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much."
Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring.
T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab.
In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects.
A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported.
44 per cent risk reduction
At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 per cent compared to standard care.
Fifteen per cent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 per cent in the THP group.
Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in.
Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimising how long patients remain on the treatment, particularly those showing complete remission.
"This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study. - AFP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sinar Daily
3 hours ago
- Sinar Daily
New hope for patients with less common breast cancer
WASHINGTON - A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported recently. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15-20 per cent of all breast cancer cases. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. - 123RF file photo HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. "Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart bomb' This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney. "Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much." Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 per cent risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 per cent compared to standard care. Fifteen per cent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 per cent in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimising how long patients remain on the treatment, particularly those showing complete remission. "This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study. - AFP
Malaysian Reserve
15 hours ago
- Malaysian Reserve
Over 4,400 Riders Embark on Ride to Conquer Cancer, Canada's Largest Athletic Fundraiser, Raising Over $20.61 Million for Life-Saving Research
Riders Begin 2-Day, 200+ KM Journey in Support of The Princess Margaret for a World Free From the Fear of Cancer TORONTO, June 7, 2025 /CNW/ – The 18th annual The Princess Margaret Ride to Conquer Cancer, presented by Johnson & Johnson, commenced this morning with over 4,000 riders departing from Sherway Gardens, Toronto in a group peloton. At the same time, more than 400 riders began their journey from the Niagara-on-the-Lake start line. Both groups will converge at McMaster University in Hamilton for overnight camp later today. This year's Ride sets a record for funds raised with $20.61 million, surpassing the previous record of $20.6 million set in 2024. United in their mission to create a world free from the fear of cancer, all riders are taking on the two-day, 200+ km journey to Niagara-on-the-Lake in support of Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment centres. 'Cancer remains one of the greatest global health threats of our time,' said Dr. Miyo Yamashita, President and CEO of The Princess Margaret Cancer Foundation. 'Yet, through the unwavering dedication of our Ride community— riders, donors, supporters and volunteers, together we are transforming the way cancer is understood, prevented, diagnosed and treated in Canada and around the world.' Among the riders was Dana Fox, who knows firsthand the importance of this cause. Diagnosed with cholangiocarcinoma, a rare and aggressive cancer, Dana is currently undergoing treatment at The Princess Margaret but is committed to completing the 200km journey. 'You are fueling hope, you are funding discovery, and you are changing lives,' Dana rallied to the crowd in his opening ceremony's patient remarks. 'This isn't just a fundraiser. This is a movement.' Participants have collectively raised an astounding $20.61 million this year, bringing The Ride's all-time fundraising total to more than $320.61 million since its inception in 2008. These funds directly support life-saving cancer research and patient care at Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment The Ride's 2025 Honourary Chairs, Nicholas and Lia Fidei said, 'After witnessing some of the success stories and meeting cancer patients who have overcome cancer, there is no doubt in our minds how much we need to support The Ride and the advancements in cancer research that The Princess Margaret is renowned for.' Nicholas, President of Treasure Hill and President of the Nicholas Fidei Foundation, and this year's top individual fundraiser also added, 'No other fundraising event that I have participated in has inspired me to greater achievements.' All riders are now making their way to Hamilton, where they'll be welcomed by cheering family and friends, enjoy a hot meal at camp ceremonies and spend the night at McMaster University. On Day 2, they'll continue their journey to the finish line at Peller Estates Winery in Niagara-on-the-Lake. For more information, to donate or to register for the 2026 Ride to Conquer Cancer, please visit ABOUT PRINCESS MARGARET CANCER FOUNDATION The Princess Margaret Cancer Foundation is Canada's largest cancer charity. We're dedicated to raising funds for Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment centres, known for its breakthrough discoveries that transform patient outcomes. Together, our work benefits cancer patients everywhere in our mission to create a world free from the fear of cancer. Through philanthropy, fundraising events, and our world-leading lottery program, we're changing how the world understands, prevents, diagnoses, and treats cancer, benefitting patients at The Princess Margaret, throughout Canada, and around the world.
Free Malaysia Today
5 days ago
- Free Malaysia Today
New hope for patients with less common breast cancer
Results from a new study could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer. (Envato Elements pic) WASHINGTON : A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer – the advanced stage of a form that comprises 15–20% of all breast cancer cases. HER2-positive cancers are fuelled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. 'Seeing such a striking improvement was really impressive to us – we were taking a standard and almost doubling how long patients could have their cancer controlled for,' oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart bomb' This 'smart bomb' strategy allows the drug to target cancer cells directly. 'You can bind to the cancer cell and dump all that chemo right into the cancer cells,' explained Tolaney. 'Some people call them smart bombs because they're delivering chemo in a targeted fashion – which is how I think we're able to really increase efficacy so much.' Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a 'second-line' option – used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled — but those results haven't yet been reported. 44% risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44% compared to standard care. Meanwhile, 15% of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5% in the THP group. Because this was an interim analysis, the median progression-free survival – meaning the point at which half the patients had seen their cancer return or worsen – was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission. 'This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer,' said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study
